RVMD Revolution Medicines, Inc. - Common Stock

NAS · US · Healthcare · Biotechnology · revmed.com

206.52USD-0.06%Mkt Cap: 44.29B $P/E: —Today

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that bind…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

BBIO

BridgeBio Pharma, Inc. - Common Stock

$13.15BUSD

Key Statistics

Company

Market Cap44.29B USD

Enterprise Value41.54B USD

Revenue (TTM)—

Gross Profit-1.30B USD

Net Income (TTM)-1.13B USD

Revenue/Share—

Last Price206.52 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees883

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-35.44

PEG—

EV/EBITDA-25.67

EV/Revenue—

P/S—

P/B27.58

EPS (TTM)-8.87

EPS (Forward)-5.83

52W Range

42.1892% of range220.81

52W High220.81 USD

52W Low42.18 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-69.35%

ROA-48.05%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-897.74M USD

CapEx (TTM)15.99M USD

FCF Margin—

FCF Yield-1.61%

Net Debt-2.75B USD

Net Debt/EBITDA1.70

Balance Sheet

Debt/Equity0.10

Current Ratio11.38

Quick Ratio11.12

Book Value/Sh7.49 USD

Cash/Share18.37 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.3 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)257.47 USD

Upside (mean)+24.7%

Target Range179.00 USD – 320.00 USD

179.00+24.7% to mean320.00

# Analysts22

Ownership

Shares Out.214.34M

Float184.55M

Insiders1.85%

Institutions100.98%

Short Interest

Short Ratio5.5d

Short % Float4.76%

Short % Out.4.51%

Shares Short9.67M

Short (prev mo.)9.72M

Technical

SMA 50202.39 (+2.0%)

SMA 200145.93 (+41.5%)

Beta1.41

S&P 52W Chg14.58%

Avg Vol (30d)1.91M

Avg Vol (10d)2.15M

Technical Indicators

RSI (14)55.6

MACD1.0660

MACD Signal0.9958

MACD Hist.+0.0701

BB Upper215.71 USD

BB Middle203.77 USD

BB Lower191.83 USD

BB Width11.72%

ATR (14)7.867 USD

Vol Ratio (20d)0.77x